{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:14:35Z","timestamp":1788470075335,"version":"build-2803163510"},"reference-count":33,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CEOR"],"DOI":"10.2147\/ceor.s417922","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T05:00:12Z","timestamp":1690520412000},"page":"607-619","source":"Crossref","is-referenced-by-count":5,"title":["The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis"],"prefix":"10.2147","volume":"Volume 15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7783-5926","authenticated-orcid":true,"given":"Nanna","family":"Nyholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-5186","authenticated-orcid":true,"given":"Anne","family":"Dan\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-5607","authenticated-orcid":true,"given":"Henrik","family":"Schnack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Lorenzo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-021-00518-8","volume":"11","author":"Papp","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"m1590","DOI":"10.1136\/bmj.m1590","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"Rendon","year":"2019","journal-title":"IJMS"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/jdv.14114","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3390\/ijms18112297","volume":"18","author":"R\u00f8nholt","year":"2017","journal-title":"IJMS"},{"key":"ref6","first-page":"934","volume":"19","author":"Nast","year":"2021","journal-title":"JDDG"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"Thatiparthi","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PTT.S356568","volume":"12","author":"de Ruiter","year":"2022","journal-title":"PTT"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2174\/1389200216666141208151524","volume":"15","author":"Tobin","year":"2015","journal-title":"CDM"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1080\/09546634.2020.1743811","volume":"33","author":"Yasmeen","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946","volume":"92","author":"ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","volume":"111","author":"Furue","year":"2018","journal-title":"Cytokine"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"Pina Vegas","year":"2022","journal-title":"JAMA Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nbt0115-3","volume":"33","author":"Ratner","year":"2015","journal-title":"Nat Biotechnol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"Torres","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1080\/13696998.2021.1970953","volume":"24","author":"Egeberg","year":"2021","journal-title":"J Med Econ"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"Torres","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","volume":"107","author":"Burgos-Pol","year":"2016","journal-title":"Actas Dermo Sifiliogr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/PTT.S367744","volume":"12","author":"Ruggiero","year":"2022","journal-title":"PTT"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","volume":"12","author":"Armstrong","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1080\/03007995.2023.2214046","volume":"39","author":"Nyholm","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"ref23","unstructured":"European Medicines Agency. Bimzelx\u00ae: summary of product characteristics; 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf. Accessed July 12, 2023."},{"key":"ref24","unstructured":"European Medicines Agency. Cosentyx\u00ae: summary of product characteristics; 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf. Accessed July 12, 2023."},{"key":"ref25","unstructured":"European Medicines Agency. Kyntheum\u00ae: summary of product characteristics; 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kyntheum-epar-product-information_en.pdf. Accessed July 12, 2023."},{"key":"ref26","unstructured":"European Medicines Agency. Taltz: summary of product characteristics; 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf. Accessed July 12, 2023."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1111\/ced.15288","volume":"47","author":"Egeberg","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s13555-021-00559-z","volume":"11","author":"Gambardella","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref29","unstructured":"Codifa. Codifa - L\u2019Informatore Farmaceutico [Codifa - Pharmaceutical Informer]; 2022. Available from: https:\/\/www.codifa.it\/. Accessed July 12, 2023."},{"key":"ref30","unstructured":"ABDATA Pharma-Daten-Service. Pharmaceutical manufacturer prices in Germany; 2023."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1080\/09546634.2020.1793891","volume":"33","author":"Augustin","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"ref32","unstructured":"Agenzia Italiana del Farmaco. Modifica dell\u2019allegato n. 2 della determina n. 285\/2022 del 27 giugno 2022, concernente procedura pay-back 5% [Amendment of attachment no. 2 of decision n. 285\/2022 of 27 June 2022, concerning the 5% pay-back procedure]; 2022. Available from: https:\/\/www.aifa.gov.it\/. Accessed July 12, 2023."},{"key":"ref33","unstructured":"Di Matteo S, Cavaliere A, Danesi R. Terapie biologiche e sequenze di trattamento per i pazienti con psoriasi a placche moderata-grave: un\u2019analisi farmacoeconomica per il Sistema Sanitario Nazionale italiano. Clinico Economics; 2022. Available from: http:\/\/www.clinicoeconomics.eu\/articles\/flipbook\/17_2022_137-154\/. Accessed July 12, 2023."}],"container-title":["ClinicoEconomics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=91561","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=91561","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T05:00:25Z","timestamp":1690520425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/the-cost-effectiveness-of-anti-il17-biologic-therapies-for-moderate-to-peer-reviewed-fulltext-article-CEOR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":33,"URL":"https:\/\/doi.org\/10.2147\/ceor.s417922","relation":{},"ISSN":["1178-6981"],"issn-type":[{"value":"1178-6981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}